Scientific Opinion on the substantiation of health claims related to
5-hydroxytryptophan and enhancement of mood (ID 1575) and attention
(ID 1828) pursuant to Article 13(1) of Regulation (EC) No 1924/2006[sup]1[/sup]
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2
European Food Safety Authority (EFSA), Parma, Italy
Słowa kluczowe:
5-Hydroxytryptophan
attention
health claims
mood enhancement
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claim is “5-hydroxytryptophan”.
5-Hydroxytryptophan is naturally present in food and can be measured by established methods.
The Panel considers that the food constituent, 5-hydroxytryptophan, which is the subject of the health claim is sufficiently characterised.
2. Znaczenie oświadczenia dla zdrowia człowieka
2.1. Poprawa nastroju (ID 1575)
The claimed effect is “mood enhancement”. The Panel assumes that the target population is the general population.
Enhancement of mood is measurable by established methods.
The Panel considers that enhancement of mood might be beneficial to human health.
2.2. Uwaga (ID 1828)
The claimed effect is “mental state and performance”. The Panel assumes that the target population is the general population.
In the context of the proposed wording, the Panel assumes that the claimed effects relate to concentration and reduction of restlessness. Concentration can be interpreted as attention which can be assessed by standard test methods. Restlessness is not a defined psychological construct.
The Panel considers that normal attention might be beneficial to human health.
3. Naukowe uzasadnienia wpływu na zdrowie człowieka
3.1. Poprawa nastroju (ID 1575)
Three references were cited to substantiate the claim. One was a narrative review, another was a Cochrane review of studies on various forms of clinically depressed patients. The third was a study of the effects of 5-HTP in combination with chlorimipramine in clinically depressed patients. The Panel notes that the evidence provided does not establish that clinically depressed patients are representative of the general population with regard to mood enhancement, or that results obtained in studies with clinically depressed subjects can be extrapolated to mood enhancement in the general population.
The Panel concludes that a cause and effect relationship has not been established between the dietary intake of 5-HTP and mood enhancement.
3.2. Uwaga (ID 1828)
Four references were cited to substantiate the claim. All four studies addressed different types of patients with anxiety, panic and sleep disorders. The Panel considers that the evidence provided does not establish that clinically ill patients with anxiety, panic and sleep disorders are representative of the general population with regard to normal attention, or that results obtained in studies on subjects with anxiety, panic and sleep disorders can be extrapolated to normal attention in the general population.
The Panel concludes that a cause and effect relationship has not been established between the dietary intake of 5-HTP and normal attention.
Wnioski
On the basis of the data available, the Panel concludes that:
The food constituent, 5-hydroxytryptophan, which is the subject of the health claim is sufficiently characterised.
Enhancement of mood (ID 1575)
The claimed effect is “mood enhancement”. The target population is assumed to be the general population. Enhancement of mood might be beneficial to human health.
A cause and effect relationship has not been established between the dietary intake of 5- hydroxytryptophan and “enhancement of mood”.
Attention (ID 1828)
The claimed effect is “mental state and performance”. The target population is assumed to be the general population. Normal attention might be beneficial to human health.
A cause and effect relationship has not been established between the dietary intake of 5- hydroxytryptophan and attention.
